Xencor, Inc. – NASDAQ:XNCR
Founder-led company
Xencor stock price today
$7.74
-16.54
-68.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Xencor stock price monthly change
+23.24%
month
Xencor stock price quarterly change
+23.24%
quarter
Xencor stock price yearly change
+15.06%
year
Xencor key metrics
Market Cap | 1.67B |
Enterprise value | 1.64B |
P/E | -30.05 |
EV/Sales | 11.49 |
EV/EBITDA | -38.35 |
Price/Sales | 11.42 |
Price/Book | 2.24 |
PEG ratio | 0.18 |
EPS | -2.19 |
Revenue | 162.18M |
EBITDA | -129.48M |
Income | -133.35M |
Revenue Q/Q | -32.47% |
Revenue Y/Y | 65.41% |
Profit margin | -38.6% |
Oper. margin | -57.69% |
Gross margin | 21.11% |
EBIT margin | -57.69% |
EBITDA margin | -79.84% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeXencor stock price history
Xencor stock forecast
Xencor financial statements
Average Price Target
$30
Potential upside: 287.59%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 45.52M | -21.95M | -48.23% |
|---|---|---|---|
| Sep 2023 | 59.16M | -24.26M | -41.02% |
| Dec 2023 | 44.68M | -19.1M | -42.74% |
| Mar 2024 | 12.80M | -68.03M | -531.3% |
| Jun 2023 | 778121000 | 99.24M | 12.75% |
|---|---|---|---|
| Sep 2023 | 778430000 | 109.42M | 14.06% |
| Dec 2023 | 952692000 | 283.55M | 29.76% |
| Mar 2024 | 884255000 | 272.06M | 30.77% |
| Jun 2023 | -38.2M | -1.40M | 1.92M |
|---|---|---|---|
| Sep 2023 | -27.28M | 45.32M | 356K |
| Dec 2023 | 181.20M | -202.63M | 22.98M |
| Mar 2024 | -55.25M | 32.31M | 186K |
Xencor alternative data
| Aug 2023 | 281 |
|---|---|
| Sep 2023 | 281 |
| Oct 2023 | 281 |
| Nov 2023 | 281 |
| Dec 2023 | 281 |
| Jan 2024 | 281 |
| Feb 2024 | 281 |
| Mar 2024 | 280 |
| Apr 2024 | 280 |
| May 2024 | 280 |
| Jun 2024 | 280 |
| Jul 2024 | 280 |
Xencor other data
44.01%
-55.99%
of XNCR is owned by hedge funds
123
-66
26.25M
-35.03M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 53 | 54108 |
| Mar 2024 | 0 | 47243 |
| May 2024 | 0 | 4745 |
| Jul 2024 | 0 | 36329 |
| Sep 2024 | 0 | 14519 |
| Nov 2024 | 0 | 121328 |
| Dec 2024 | 0 | 14722 |
| Patent |
|---|
Application Filling date: 17 May 2022 Issue date: 8 Sep 2022 |
Grant Utility: Heterodimeric Fc variants Filling date: 13 Aug 2019 Issue date: 2 Aug 2022 |
Application ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS Filling date: 23 Dec 2021 Issue date: 21 Jul 2022 |
Application Filling date: 18 Jan 2022 Issue date: 7 Jul 2022 |
Grant Utility: PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof Filling date: 11 Oct 2019 Issue date: 5 Jul 2022 |
Application Filling date: 16 Mar 2022 Issue date: 30 Jun 2022 |
Application Filling date: 11 Mar 2022 Issue date: 23 Jun 2022 |
Grant Filling date: 8 Jun 2017 Issue date: 21 Jun 2022 |
Grant Filling date: 10 Sep 2013 Issue date: 21 Jun 2022 |
Grant Filling date: 3 Oct 2019 Issue date: 14 Jun 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
Xencor: Data In Early 2024 Could Bring Shareholder Value
Xencor: A Mid-Stage Clinical Company With Falling Losses
Xencor: Capital-Efficient Platform Tech Play With A Lot Going On
Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xencor In $480 Million Deal
-
What's the price of Xencor stock today?
One share of Xencor stock can currently be purchased for approximately $7.74.
-
When is Xencor's next earnings date?
Unfortunately, Xencor's (XNCR) next earnings date is currently unknown.
-
Does Xencor pay dividends?
No, Xencor does not pay dividends.
-
How much money does Xencor make?
Xencor has a market capitalization of 1.67B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.28% to 168.34M US dollars.
-
What is Xencor's stock symbol?
Xencor, Inc. is traded on the NASDAQ under the ticker symbol "XNCR".
-
What is Xencor's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Xencor?
Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Xencor's key executives?
Xencor's management team includes the following people:
- Dr. Bassil I. Dahiyat Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 55, pay: $971,930)
- Dr. Allen S. Yang M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 57, pay: $678,930)
- Dr. John R. Desjarlais Senior Vice President of Research & Chief Scientific Officer(age: 61, pay: $637,930)
- Mr. John J. Kuch Senior Vice President & Chief Financial Officer(age: 66, pay: $584,930)
- Ms. Celia E. Eckert J.D. Vice President, Gen. Counsel & Corporation Sec.(age: 53, pay: $572,860)
-
Is Xencor founder-led company?
Yes, Xencor is a company led by its founder Dr. Bassil I. Dahiyat Ph.D..
-
How many employees does Xencor have?
As Jul 2024, Xencor employs 280 workers.
-
When Xencor went public?
Xencor, Inc. is publicly traded company for more then 11 years since IPO on 3 Dec 2013.
-
What is Xencor's official website?
The official website for Xencor is xencor.com.
-
Where are Xencor's headquarters?
Xencor is headquartered at 111 West Lemon Avenue, Monrovia, CA.
-
How can i contact Xencor?
Xencor's mailing address is 111 West Lemon Avenue, Monrovia, CA and company can be reached via phone at +62 630 55900.
-
What is Xencor stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Xencor in the last 12 months, the avarage price target is $30. The average price target represents a 287.59% change from the last price of $7.74.
Xencor company profile:
Xencor, Inc.
xencor.comExchange:
NASDAQ
Full time employees:
280
Industry:
Biotechnology
Sector:
Healthcare
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
111 West Lemon Avenue
Monrovia, CA 91016
Monrovia, CA 91016
CIK: 0001326732
ISIN: US98401F1057
CUSIP: 98401F105
